Inclusion Criteria:

Consenting patients (age 12-70) will be eligible for participation in the study involving
anti-tumor immunotherapy provided the following criteria are met:

1. Evidence of cancer not expected to be cured with conventional modalities:

Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 & sarcomas. Adult
patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and
selected cases of ovary cancer, gastrointestinal cancer, small-cell and non-small
cell lung cancer with non-bulky metastatic disease, metastatic prostate cancer.

2. Patients with measurable disease evaluable for response with anticipated life
expectancy >3 months.

3. Patients must be >2 weeks off anti-cancer or potentially immunosuppressive treatment.

4. Adequate ambulatory performance status (Karnofsky >80%; ECOG 0-1) to enable
outpatient treatment (see Appendix 1).

5. Compliant and cooperative patients anticipated to be evaluable for response according
to investigator's assessment.

6. HLA-noncompatible (partial matched or mismatched) donor available.

Exclusion Criteria:

Patients will be excluded from participation in the study if any of the following criteria
are met:

1. Any of the above criteria are not met.

2. Patients with a significant history or current evidence of potentially severe
cardiovascular disease.

3. Hepatic and/or renal failure.

4. Abnormal PT and PTT.

5. Patients with abnormal hemogram (PMN<1.0x109/L; HB<10; Plts<50x109/L)

6. Evidence of serious active infection requiring antibiotic therapy.

7. Evidence of active disease requiring steroid or cytotoxic therapy.

8. Pregnancy.

9. Contraindication for donation due to donor disease: HIV-1; HBsAg positivity.